跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
RADICAVA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
RADICAVA
Authorized
STANDARD
RADICAVA
MITSUBISHI TANABE PHARMA CORPORATION
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
5f9e21f6d336c8eb
Company
MITSUBISHI TANABE PHARMA CORPORATION
Type
Standard
Approval Details
Approval Id
5f9e21f6d336c8eb
Drug Approval Canada Name
RADICAVA
Product Name
RADICAVA
Status
Marketed
Status Date
2023-02-09
Original Market Date
2023-02-09
Din
02532611
Drug Class
Human
Dosage Form
Suspension
Route Of Administration
Oral
Schedule
Prescription
Ahfs
28:44.00
Atc Original
N07XX14 EDARAVONE
Atc Name
n 07 xx 14
Aig Number
0160190002
Company Name
MITSUBISHI TANABE PHARMA CORPORATION
Company Address
3-2-10 Doshomachi, Chuo-Ku, Osaka-Fu, Japan, 541-0045
Company Detail Path
/organization/mitsubishi-tanabe-pharma-corporation
Company Information
Pharmaceutical Company Name
MITSUBISHI TANABE PHARMA CORPORATION
Country Name
Japan
Province Name
yamagata,country_jp
City Name
yamagata,yamagata,country_jp
Address
2-2-36, KASUMICHO
Active Ingredients
EDARAVONE
105 MG / 5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
5f9e21f6d336c8eb
Type
Standard
Back to Health Canada Approvals